AbMax AntibodyChina (China)

AbMax AntibodyChina (China), operating as 京天成生物技术（北京）有限公司 (Jing Tian Cheng Biotechnology (Beijing) Co., Ltd.), is a Beijing-based national high-tech enterprise founded in 2006. The company provides a one-stop antibody and kit development technology platform and an antibody humanization platform. According to its official website, its monoclonal antibody development averages 46 days with a success rate of up to 90%. It has undertaken multiple national and Beijing municipal science and technology program projects, maintains deep cooperation with well-known domestic and international research institutions and enterprises, and has established a quality management system compliant with GLP standards. The company's core business spans vaccine-related reagents, biopharmaceutical-related reagents, diagnostic raw materials, and technical services including custom antibody development, kit R&D, one-stop antibody drug development, methodology development and sample analysis, and antibody engineering for De-ADA and De-ADCC/ADCP functions. Since 2012, it has promoted vaccine component-specific mouse monoclonal antibodies and vaccine antigen quantitative detection kit development services, serving nearly a hundred domestic vaccine enterprises. Its vaccine quality-control reagents have supported non-clinical or clinical studies for multiple vaccine products, including rabies vaccines, multivalent HPV vaccines, pertussis vaccines, and pneumonia vaccines. In 2016, the company took the lead in building immunogenicity methodology in accordance with the new U.S. FDA guidelines, established a drug metabolism methodology development platform, and expanded into anti-biopharmaceutical idiotypic monoclonal and polyclonal antibody development. Relying on its antibody reagent and methodology development technology platform in the biopharmaceutical testing field, AbMax AntibodyChina currently holds approximately 50% market share in northern China and over 30% in southern China for anti-drug antibody development. In January 2020, the company independently undertook and successfully accepted one of the first five COVID-19 projects of the Beijing Municipal Science and Technology Commission, receiving 2 million yuan in funding. In the same month, it received US$100,000 from the Gates Foundation to carry out COVID-19 antibody project research. In March 2020, it established 京天成生物技术（天津）有限公司 (Jing Tian Cheng Biotechnology (Tianjin) Co., Ltd.) in the Tianjin Binhai New Area International Biomedical Joint Research Institute, receiving 3 million yuan from the Tianjin TEDA Economic and Technological Development Zone's anti-epidemic special fund. The company rents 1,100 square meters, of which 800 square meters is an experimental base. Tianjin Jing Tian Cheng builds a kit product R&D and production base on the foundation of the Beijing parent company's antibody development and methodology development. In the second half of 2023, the company began a business transformation. Based on its infectious disease pathogen monoclonal antibody library, it cooperated with regulatory authorities and multiple vaccine enterprises to jointly develop standardized antibody products and detection kit products for the vaccine quality-control field, including antigen quantification and antigen activity quantification kit products for pneumonia polysaccharides, HPV vaccines, rabies vaccines, pertussis vaccines, and herpes zoster vaccines, most of which are domestic and international originals with technological monopoly. In 2023, it achieved 3.7 million yuan in sales, a 100% increase over 2022. The company has 36 employees, including 22 scientific researchers and a 4-person sales team. Three employees hold doctoral degrees, eight hold master's degrees, and eleven hold bachelor's degrees.

AbMax AntibodyChina (China), operating as 京天成生物技术（北京）有限公司 (Jing Tian Cheng Biotechnology (Beijing) Co., Ltd.), was founded in 2006 in Beijing, China. It is a national high-tech enterprise. The company established a one-stop antibody and kit development technology platform and an antibody humanization platform. Its monoclonal antibody development averages 46 days with a success rate of up to 90%. It has undertaken multiple national and Beijing municipal science and technology program projects, maintains deep cooperation with well-known domestic and international research institutions and enterprises, and has established a quality management system compliant with GLP standards. In 2012, the company began promoting vaccine component-specific mouse monoclonal antibodies and vaccine antigen quantitative detection kit development services. To date, it has served nearly a hundred domestic vaccine enterprises. Its vaccine quality-control reagents have supported non-clinical or clinical studies for multiple vaccine products, including rabies vaccines, multivalent HPV vaccines, pertussis vaccines, and pneumonia vaccines. In 2016, the company took the lead in building immunogenicity methodology in accordance with the new U.S. FDA guidelines. It also established a drug metabolism methodology development platform and expanded into anti-biopharmaceutical idiotypic monoclonal and polyclonal antibody development. Relying on its antibody reagent and methodology development technology platform in the biopharmaceutical testing field, AbMax AntibodyChina currently holds approximately 50% market share in northern China and over 30% in southern China for anti-drug antibody development. In January 2020, the company independently undertook and successfully accepted one of the first five COVID-19 projects of the Beijing Municipal Science and Technology Commission, receiving 2 million yuan in funding. In the same month, it received US$100,000 from the Gates Foundation to carry out COVID-19 antibody project research. In March 2020, it established 京天成生物技术（天津）有限公司 (Jing Tian Cheng Biotechnology (Tianjin) Co., Ltd.) in the Tianjin Binhai New Area International Biomedical Joint Research Institute, receiving 3 million yuan from the Tianjin TEDA Economic and Technological Development Zone's anti-epidemic special fund. The company rents 1,100 square meters, of which 800 square meters is an experimental base. Tianjin Jing Tian Cheng builds a kit product R&D and production base on the foundation of the Beijing parent company's antibody development and methodology development. In the second half of 2023, the company began a business transformation. Based on its infectious disease pathogen monoclonal antibody library, it cooperated with regulatory authorities and multiple vaccine enterprises to jointly develop standardized antibody products and detection kit products for the vaccine quality-control field, including antigen quantification and antigen activity quantification kit products for pneumonia polysaccharides, HPV vaccines, rabies vaccines, pertussis vaccines, and herpes zoster vaccines, most of which are domestic and international originals with technological monopoly. In 2023, it achieved 3.7 million yuan in sales, a 100% increase over 2022. The company has 36 employees, including 22 scientific researchers and a 4-person sales team. Three employees hold doctoral degrees, eight hold master's degrees, and eleven hold bachelor's degrees.

• Company founded in Beijing, China.

• Began promoting vaccine component-specific mouse monoclonal antibodies and vaccine antigen quantitative detection kit development services.

• Took the lead in building immunogenicity methodology in accordance with the new U.S. FDA guidelines; established a drug metabolism methodology development platform and expanded into anti-biopharmaceutical idiotypic monoclonal and polyclonal antibody development.

• Independently undertook and successfully accepted one of the first five COVID-19 projects of the Beijing Municipal Science and Technology Commission, receiving 2 million yuan in funding; received US$100,000 from the Gates Foundation for COVID-19 antibody project research.

• Established Jing Tian Cheng Biotechnology (Tianjin) Co., Ltd. in the Tianjin Binhai New Area International Biomedical Joint Research Institute, receiving 3 million yuan from the Tianjin TEDA Economic and Technological Development Zone's anti-epidemic special fund.

• Began business transformation, developing standardized vaccine quality-control antibody products and detection kits based on its infectious disease pathogen monoclonal antibody library.

• Achieved 3.7 million yuan in sales, a 100% increase over 2022.

National high-tech enterprise providing one-stop antibody and kit development platforms, with a focus on vaccine quality-control reagents and immunogenicity methodology services for the biopharmaceutical industry.

• Varicella zoster virus (VZV) Quantitation Kit (ELISA)

  Sandwich ELISA for VZV antigen quantitation.

• Varicella zoster virus (VZV) gE protein Quantitation Kit (ELISA)

  Sandwich ELISA for VZV gE protein quantitation.

• Human Anti-VZV gE Antibody ELISA Kit

  ELISA kit for detecting human anti-VZV gE antibodies.

• Mouse Anti-Anti-VZV gE Antibody ELISA Kit

  ELISA kit for detecting mouse anti-VZV gE antibodies.

• VZV gE Antibody detection (Colloidal Gold)

  Colloidal gold strip for VZV gE antibody detection (coming soon).

• 24-valent pneumococcal polysaccharide monoclonal antibody

  Monoclonal antibody for 24-valent pneumococcal polysaccharide.

• Pertussis component vaccine quantitation kit

  Kit for quantitation of pertussis component vaccine.

• HPV-related reagents

  Reagents related to human papillomavirus (HPV).

• Rabies virus-related reagents

  Reagents related to rabies virus.

• Meningitis A/C/W/Y polysaccharide detection kit

  Kit for detection of A/C/W/Y meningococcal polysaccharide.

1. 1京天成生物技术（北京）有限公司antibodychina.com
2. 2京天成生物技术（北京）有限公司 - 公司简介antibodychina.com
3. 3京天成生物技术（北京）有限公司 - 公司概况antibodychina.com
4. 4京天成生物技术（北京）有限公司 - 产品antibodychina.com
5. 5AbMax AntibodyChina (China) - Wikidatawikidata.org